Elegrobart
Based on 1 Customer Validation
Elegrobart is an immunoglobulin G1-κ monoclonal antibody targeting the human insulin-like growth factor 1 receptor (IGF1R). Elegrobart is promising for research of diseases associated with abnormal IGF1R signaling, especially thyroid eye disease.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 95.27%
- CAS No.: 2832924-76-0
- Masse moléculaire:147.567 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
IGF1R/CD221
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
IgG1-kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized IGF-I R Protein, Human (HEK293, His, HY-P72606) can bind Elegrobart. The EC50 for this effect is 38.96 ng/mL.
Chemical Information
-
CAS No. 2832924-76-0
-
Appearance Liquid
-
Masse moléculaire 147.567 kDa
-
Color Colorless to light yellow
-
SMILES
[Elegrobart]
-
Synonyms
VRDN-003; ZL-1109
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Pureté et documentation
-
Fiche technique (255 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)